Folates and lipoic acid content in the hepatoprotector Prohepar


如何引用文章

全文:

详细

Prohepar is a hepatoprotector drug, based on the hydrolyzate of animal liver. The enrichment of the liver extract with standardized amounts of cyancobalamin, cysteine, choline and inositol enhances hepatoprotective properties of the drug. Since the is multi-component composition, the experimental study of its composition is important for understanding the foundations of hepatoprotective effect of the drug. In the present work we studied the vitamin content of Prohepar. It was found that the drug contains significant amounts of lipoic acid and tetrahydrofolic acid - the endogenous and the safe form of folates. Lipoic acid, as well as tetrahydrofolic acid have strong hepatoprotective properties. The study confirmed the presence of cyancobalamin in the drug in the amounts specified by the manufacturer. The presence of small amounts of other vitamins (especially vitamins C, E, B6 and B1) indicates soft conditions of the Prohepar production, which help to preserve biological activity of peptides, lipoic acid and tetrahydrofolic acid in Prohepar.

参考

  1. Волков А.Ю., Тогузов Р.Т., Назаренко О.А., Торшин И.Ю., Громова О.А. Микроэлементный состав прогепара // Клиническая фармакология и фармакоэкономика. 2010. № 6. C. 2.
  2. Alan HB, Tietz W. Clinical guide to laboratory tests, fourth edition, 2006.
  3. Bertelsmann S. Mineralstoffe, Spurenelemente und Vitamine-klinische Aspekte und chemische analyse; Verlag Bertelsmann Stiftung, Gutersloh, 1997.
  4. Mata-Granados JM, Luque De Castro MD, Quesada JM. Fully automated method for the determination of 24,25(OH)2 and 25(OH) D3 hydroxyvitamins, and vitamins A and E in human serum by HPLC. J Pharm Biomed Anal 2004, 35(3):575-82.
  5. Lee W, Roberts SM, Labbe RF. Ascorbic acid determination with an automated enzymatic procedure. Clinical Chemistry 1997;43:154-57.
  6. Кrapf FE, Bieger WP, Tiller FW. Laboratoren DatenBuch. Verlag Urban und Schwarzenberg, Munchen 1995:361.
  7. Greiling H, Gressner AM. Lehrbuch der Klinischen Chemie und Pathobiochemie. Verlag Schattaner 1995;3:458.
  8. Rychlik M. Panthotenic acid quantification by a stable isotope dilution assay based on liquid chromatography-tandem mass spectrometry. Analyst 2003;128:832-37.
  9. Cham BE, Roeser HP, Kamst TW. Simultaneous liquid-chromatographic determination of vitamin K1 and vitamin E in serum. Clin Chem 1989;35:2285-89.
  10. Teichert J, Hermann R, Ruus P, et al. Plasma kinetics, metabolism, and urinary excretion of alpha-lipoic acid following oral administration in healthy volunteers. J Clin Pharmacol 2003;43(11):1257-67.
  11. Pari L, Murugavel P. Protective effect of alpha-lipoic acid against chloroquine-induced hepatotoxicity in rats. J Appl Toxicol 2004;24(1):21-26.
  12. Muller C, Dunschede F, Koch E, et al. Alpha-lipoic acid preconditioning reduces ischemia-reperfusion injury of the rat liver via the PI3-kinase/Akt pathway. Am J Physiol Gastrointest Liver Physiol 2003;285(4):769-78.
  13. Kiemer AK, Muller C, Vollmar AM. Inhibition of LPS-induced nitric oxide and TNF-alpha production by alpha-lipoic acid in rat Kupffer cells and in RAW 264.7 murine macrophages. Immunol Cell Biol 2002;80(6):550-57.
  14. Ritschell W. Curative liver protection by thioctic acid. Pharm Acta Helv 1959;34:189-94
  15. Murabayashi A, Yamada M. Effects of the oral administration of hepatoprotective drugs on the prevention of hepatic disorders after lung surgery. Kyobu Geka 1964;17:372-74.
  16. Issekutz L. Evaluation of the therapeutic effect of live protective substances. Arzneimittelforschun 1967;17(4):419-24.
  17. Gomez Ponsa JM. 1st experiences with the use of a new liver protector in liver diseases. Rev Esp Enferm Apar Dig 1970;32(5):593-600.
  18. Moller E, Brinkmann W, Weber O, et al. Treatment of chronic liver diseases with thioctic acid. Med Klin 1967;62(10):380-84.
  19. Horakova O, Kostir J, Horak F. The hepatotropic effect of alpha-lipoic acid. Cesk Farm 1967;16(3):129-33.
  20. Iasinovskii MA, Terletskaia TM, Bondarchuk AF. Use of lipoic acid in complex therapy of patients with liver diseases. Vrach Delo 1969;5:9-12.
  21. Ivkov VG. Lipoic (thioctic) acid and its significance in hepatology. Sov Med 1969;32(10):122-28.
  22. Romanov VS. Use of lipoic acid and its amide in chronic liver diseases. Sov Med. 1971;34(12):43-45.
  23. Ребров В.Г., Громова О.А. Витамины, макро- и микроэлементы. М., 2008, С. 947.
  24. Громова О.А., Торшин И.Ю. Применение фолиевой кислоты в акушерстве и гинекологии. М., 2009, С. 73.
  25. Suitor CW, Bailey LB. Dietary folate equivalents: interpretation and application. J Am Diet Assoc 2000;100(1):88-94.
  26. Smith AD, Kim YI, Refsum H. Is folic acid good for everyone? Am J Clin Nutr 2008;87(3):517-33.
  27. Nijhout HF, Reed MC, Budu P, et al. A mathematical model of the folate cycle: new insights into folate homeostasis. J Biol Chem 2004;279(53):55008-16.
  28. Woo CW, Prathapasinghe GA, Siow YL, et al. Hyperhomocysteinemia induces liver injury in rat: Protective effect of folic acid supplementation. Biochim Biophys Acta 2006;1762(7):656-65.
  29. Boselli A. A new hepatoprotective preparation. Biochemical aspects and clinical studies. Clin Ter 1968;44(2):115-56.
  30. Tropeano L, Belfiore F. Arginase activity in the serum of guinea pigs intoxicated with carbon tetrachloride and hepatoprotective vitamin complex. Boll Soc Ital Biol Sper 1959;35:1084-86.
  31. Fanelli V. Clinical observations on a new preparation with hepatoprotective action. Clin Ter 1967;40(2):145-56.
  32. Banerjee RV, Matthews RG. Cobalamin-dependent methionine synthase. Faseb J 1990;4(5):1450-59.
  33. Wickramasinghe SN. Morphology, biology and biochemistry of cobalamin- and folate-deficient bone marrow cells. Baillieres Clin Haematol 1995;8(3):441-59.
  34. Isoda K, Kagaya N, Akamatsu S, et al. Hepatoprotective effect of vitamin B12 on dimethylnitrosamine-induced liver injury. Biol Pharm Bull 2008;31(2):309-11.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2010
##common.cookie##